STOCK TITAN
  1. Home
  2. Sec-filings
  3. ICCM
  4. [Form 3] IceCure Medical Ltd. Initial Statement of Beneficial Ownership

IceCure Medical (ICCM) director discloses shares and options in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IceCure Medical Ltd. director Mayron Ron filed an initial Form 3, detailing existing equity holdings rather than new trades. Ron holds 296,631 ordinary shares, consisting of 10,000 shares and 286,631 restricted share units, of which 107,486 have vested and 179,631 remain unvested as of March 18, 2026.

Ron also reports several fully vested share option grants over the company’s ordinary shares: 95,295 options at an exercise price of $1.55 per share expiring in 2028, 25,000 at $1.79 expiring in 2029, 25,000 at $1.68 expiring in 2030, and 110,000 at $3.64 expiring in 2032. An additional 59,295 options at $1.51 per share expiring in 2033 are partly vested, with 44,471 options vested as of March 18, 2026. This filing simply records Ron’s current ownership position.

Positive

  • None.

Negative

  • None.
Insider Mayron Ron
Role Director
Type Security Shares Price Value
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Ordinary shares -- -- --
Holdings After Transaction: Share option (right to buy) — 95,295 shares (Direct); Ordinary shares — 296,631 shares (Direct)
Footnotes (1)
  1. Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026. The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested. The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share. The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested. The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Mayron Ron
(Last)(First)(Middle)
7 HA'ESHEL ST., PO BOX 3163
(Street)
CAESAREA3079504
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares296,631(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy) (2)01/10/2028Ordinary shares95,295$1.55(3)D
Share option (right to buy) (4)05/21/2029Ordinary shares25,000$1.79(5)D
Share option (right to buy) (6)10/28/2030Ordinary shares25,000$1.68(7)D
Share option (right to buy) (8)01/12/2032Ordinary shares110,000$3.64(9)D
Share option (right to buy) (10)02/19/2033Ordinary shares59,295$1.51(11)D
Explanation of Responses:
1. Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026.
2. The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested.
3. The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share.
4. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested.
5. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.
6. The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.
7. The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share.
8. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested.
9. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
10. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested.
11. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
/s/ Ron Mayron03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the IceCure Medical (ICCM) Form 3 filing by Mayron Ron show?

The Form 3 shows existing ownership for director Mayron Ron, not new trades. It details his current ordinary share, RSU, and stock option holdings in IceCure Medical, providing a baseline of his equity position as of March 18, 2026.

How many IceCure Medical (ICCM) ordinary shares does Mayron Ron beneficially own?

Mayron Ron reports 296,631 ordinary shares of IceCure Medical. This includes 10,000 ordinary shares and 286,631 restricted share units, of which 107,486 have vested and 179,631 remain unvested as of March 18, 2026.

What stock options in IceCure Medical (ICCM) does Mayron Ron hold according to the Form 3?

Ron holds several share option grants over ordinary shares: 95,295 options at $1.55, 25,000 at $1.79, 25,000 at $1.68, 110,000 at $3.64, and 59,295 at $1.51, each with stated future expiration dates.

Are Mayron Ron’s IceCure Medical (ICCM) options vested or unvested?

As of March 18, 2026, all options from the 2018, 2019, 2020, and 2022 grants are fully vested. From the 2023 grant, 44,471 options are vested, while the remaining portion continues to vest in equal quarterly installments of 6.25%.

Does the IceCure Medical (ICCM) Form 3 indicate that Mayron Ron bought or sold shares?

The Form 3 does not report any new purchases or sales. It is an initial statement of beneficial ownership, listing Ron’s existing ordinary shares, RSUs, and option holdings as of the reporting date.

What are the expiration dates of Mayron Ron’s IceCure Medical (ICCM) stock options?

Ron’s option grants over ordinary shares expire on January 10, 2028, May 21, 2029, October 28, 2030, January 12, 2032, and February 19, 2033, aligning with their respective grant and vesting schedules.